Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review.
Dementia with Lewy bodies
GBA1 gene
Gaucher disease
Glucocerebrosidase
Journal
Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
19
06
2022
revised:
01
09
2022
accepted:
02
09
2022
pubmed:
10
9
2022
medline:
28
9
2022
entrez:
9
9
2022
Statut:
ppublish
Résumé
Dementia with Lewy bodies (DLB) is a neurodegenerative disease linked to abnormal accumulation of phosphorylated α-synuclein. GBA1 is the gene encoding the lysosomal enzyme glucocerebrosidase (GCase), whose mutations are a risk factor of DLB. To report all available data exploring the association between GBA1 mutations and DLB. All publications focused on GCase and DLB in humans between 2003 and 2022 were identified on PubMed, Cochrane and ClinicalTrials.gov. 29 studies were included and confirmed the strong association between GBA1 mutations and DLB (Odds Ratio [OR]: 8.28). GBA1 mutation carriers presented a more malignant phenotype, with earlier symptom onset, more severe motor and cognitive dysfunctions, more visual hallucinations and rapid eye movement sleep disorder. GBA1 mutations were associated with "purer" neuropathological DLB. No therapeutic recommendations exist and clinical trials targeting GCase are just starting in DLB patients. This review reports a link between GBA1 mutations and the DLB phenotype with limited evidence due to the small number of studies.
Identifiants
pubmed: 36084847
pii: S0149-7634(22)00345-1
doi: 10.1016/j.neubiorev.2022.104856
pii:
doi:
Substances chimiques
alpha-Synuclein
0
Glucosylceramidase
EC 3.2.1.45
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104856Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.